Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Phillip Capital

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2051.9000 61.00 (3.06%)

NSE Sep 05, 2025 15:31 PM

60.87% Gain from 52W Low

Volume: 977.4K

Glenmark Pharmaceuticals Ltd.

30 Jan 2016

2051.90

3.06%

Glenmark 30Jan2016

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Phillip Capital

However, margin performance was just about in line as improving revenue mix towards bettermargindomestic/USbusinessraisedEBITDAmarginsby80bpsto22.6%.Ledbylower salesandhighertaxincidenceof33%,PAT(adjustedforforexlossofRs270mn)was19%...

Glenmark Pharmaceuticals Ltd. has gained 29.47% in the last 3 Months